Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomised controlled trial

Title	Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomised controlled trial
Authors	Sergei Krasny, Yauheni Baranau, Sergey Polyakov, Ekaterina Zharkova, Olga Streltsova, Aliona Filimonava, Volha Siarheyeva, Sviatlana Kazlouskaya, Anton Khorau, Vladimir Gabai, Alexander Shneider
Magazine	Frontiers in Oncology
Date	02/12/2024
DOI	https://doi.org/10.3389/fonc.2024.1343023
Introduction	This study evaluates the combined efficacy and safety of ELENAGEN, a novel DNA plasmid encoding p62/SQSTM1 protein, with gemcitabine chemotherapy in platinum-resistant ovarian cancer patients. Conducted as an open-label, randomised trial, the investigation involved two groups: one receiving only gemcitabine and the other receiving gemcitabine supplemented with ELENAGEN. Progression-free survival (PFS) was the primary endpoint, while safety was the secondary endpoint. Results indicated that ELENAGEN significantly improved median PFS to 7.2 months compared to 2.8 months in the control group. Notably, ELENAGEN showed high efficacy in patients with poor prognostic indicators, such as high CA125 levels and rapid progression post-platinum-free interval. The trial confirms ELENAGEN's potential to enhance outcomes in challenging ovarian cancer cases.
Quote	Sergei Krasny, Yauheni Baranau and Sergey Polyakov et al. Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomised controlled trial. Front Oncol. 2024. Vol. 14. DOI: 10.3389/fonc.2024.1343023
Element	Platinum (Pt)
Industry	Pharmaceutical Industry